USFDA finds Innoxel facility ready for commercial operations

Regulatory & Legal View source PDF Explain this filing

BPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.2%Reaction day

₹1790.10

prior close

₹1827.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 171sector+0.5%+1.7% vs sector

On the reaction day the stock moved 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.5

15m

+0.3

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.2pendingpending+0.5+1.7

Next day

+6.1pendingpending+0.4+5.7

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Innoxel Lifesciences, Bharat Parenterals' subsidiary, received a USFDA Establishment Inspection Report after an unannounced pre-approval inspection at its Vadodara injectable plant from April 13 to 20, 2026. The FDA closed the inspection with no further questions and found the site ready to support commercial production of the inspected general injectable. This was the site's second EIR, and Innoxel began US commercial supply in October 2026.

Likely market impact

Positive for Bharat Parenterals by supporting Innoxel's US credibility and prospects for new manufacturing contracts. No financial guidance was given.